Year: 2017
Type: review
Abstract: Immunotherapy has recently emerged as the fourth pillar of cancer treatment, joining surgery, radiation, and chemotherapy. While early immunotherapies focused on accelerating T-cell activity, current immune-checkpoint inhibitors take the brakes off the anti-tumor immune responses. Successful clinical trials with PD-1 monoclonal antibodies and other immune-checkpoint inhibitors have opened new avenues in cancer immunology. However, the failure of a large subset of cancer patients to respond to these new immunotherapies has led to intensified research on combination therapies and predictive biomarkers. Here we summarize the development of PD-1-blockade immunotherapy and current issues in its clinical use.
Source: Journal of Biomedical Science
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
Awards: Clinical utilization and investigation of ovarian cancer genome diversity associated with metastasis, resistance to treatment and immune escape, Elucidation of anti-tumor immune mechanism including Treg inhibition by PD-1 blockade., Investigation of acquired resistance of PD-1 inhibitor with recycle of CART system
OpenAlex ID: W2604909450
